Pfizer Norvasc Patent: Will Court Limit Extension To “Approved” Product?

Dr. Reddy's reliance on Norvasc data in its 505(b)(2) application for amlodipine maleate could impact an appeals court's determination of whether Pfizer's patent term extension applies only to the approved besylate salt form of the drug

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet